Why Academic Clinical Research Runs on a Decade-Old Stack

Clinical research at academic institutions runs on a stack that was chosen for it rather than by it—the good tools are built and priced for the pharmaceutical industry, and the free ones are a decade behind what protocols now require. As a result, the institutions training the next generation of researchers can't access the methods that generation will spend its career using. In this first post, we break down the major challenges academic and research institutions face when conducting clinical research and human clinical trials.

Built for Pharma, Priced for Pharma

Modern clinical research is defined by commercial platforms built specifically for drug development. Medidata Rave, Veeva Vault CDMS, and Oracle Clinical One are built around site-based, IND-oriented trials with monitoring, source data verification, and submission-ready outputs. Their product is coherent, but their pricing is less so—quotes are scoped to sponsor budgets, which tells you who the customer is, and more importantly, who the customer is not.

An investigator running a twelve-week sleep intervention with 200 participants and a wearable endpoint is not that customer. Neither is a nutrition study, a behavioral trial, a digital biomarker validation, a device evaluation, or an observational cohort. Those teams get quoted for infrastructure built around a regulatory pathway they aren't on, at a price set by companies whose comparison case is a Phase III program.

Even for the teams that find a tool priced and built for their kind of study, procurement narrows the field again. Before a study can run on a platform, that platform has to clear three obstacles: human subjects review, information security review, and contracting. Most institutions also require vendors to complete the Higher Education Community Vendor Assessment Toolkit (HECVAT)—321 questions across seven sections—and resubmit it every year. A tool that's already approved skips this process, which is why already-approved tools keep winning.

So teams use REDCap. It's free, it's familiar to the IRB, and hosting sits with an informatics core rather than the lab. It's the sensible decision, but it's also where the next problem starts. REDCap manages forms well, but its capacity for other types of data collection is limited. It doesn't integrate continuous wearable streams, instruments that open only between noon and 2 p.m., participant-facing schedules and progress, or payments released against protocol milestones. REDCap leaves teams with limited options: build alongside it, or drop the part of the protocol the tool can't support.

The Lag, and Who Pays for It

Over the past decade, the most influential and innovative tools in human research have reached academic teams last. Decentralized designs, for example, are established—the FDA has issued guidance on conducting clinical trials with decentralized elements. Consumer wearables and sensors now generate continuous physiological data at a scale no visit schedule can match. At-home biomarker collection removes a phlebotomy appointment from a protocol. AI-powered digital biomarkers, and even study design tools for protocol design, adherence monitoring, and analysis, are already in production at commercial research organizations. None of these tools are speculative and none of them are unproven—they're just inaccessible, priced for sponsors, sold to sponsors, and adopted by sponsors first.

Academic institutions access new technologies eventually, typically through an industry sponsor bringing the tooling in as part of a collaboration—in which case, the capability arrives attached to someone else's study and leaves with it. Otherwise, students encounter the tooling after they leave, in an industry job, three years after the training that was supposed to prepare them for it.

This is a problem for the field, and a matter of fairness. Faculty can't teach methods they can't access, so curricula stay current with the tools available on campus instead of the tools the field actually runs on. Students graduate fluent in form-based data capture and unfamiliar with continuous measurement, remote protocols, and automated adherence. And the diffusion runs the wrong direction—every trainee who learns a method in graduate school carries it into every institution they work at afterward. Academic labs are the widest distribution channel research methodology has, and they're being served last.

The Cost Nobody Can Put in a Budget

Still, the gap persists because closing it requires substantial funding that usually isn't there. One seeming alternative is building custom software in-house. But custom infrastructure is never free—its cost just shows up in other places, billed as something else. The expenses are difficult to see, and therefore difficult to fund. When a lab assembles its own participant tracking, consent flow, wearable ingestion, and compensation process, that work is paid for but recorded as something different: coordinator hours, a postdoc's uncredited second job, four months between award notice and first enrollment. Nobody writes "build our own study platform" into an aims page, so the cost is real, recurring, and invisible to the grant absorbing it. It's also fragile—the pipeline works until the person who wrote it defends their thesis, and research code routinely becomes unusable once a project ends or its developer leaves.

Beyond being unsustainable internally, custom infrastructure is difficult to reconcile with compliance standards. The NIH Data Management and Sharing Policy requires investigators to plan and budget for data management at application; the approved plan becomes a term and condition of the award, and NIH has required a standardized questionnaire and data table since May 25, 2026. Teams with structured collection satisfy this by doing nothing extra. Teams working across spreadsheets satisfy it by reconstructing the study after it ends.

This isn't just a tooling issue—it creates real cost exposure, moreover, the ground on which institutions make these decisions is destabilizing in ways that make custom solutions riskier. Courts blocked a proposed 15% cap on indirect costs, and agencies cannot alter indirect reimbursement until September 30, 2026. Indirect recovery is what pays for research infrastructure and the staff who maintain it, so labs are committing to systems that will outlast the certainty of funding them. The workaround of custom infrastructure is unsustainable under mounting external pressure.

Then there's the chicken-and-egg problem at the front of every project. Competitive R01 applications are expected to arrive with pilot data already collected, which is why institutions keep small internal awards specifically to generate preliminary results for R01 submissions. Those funds are limited and oversubscribed. A feasibility study needs money, and the money needs a feasibility study. The costs aren't just invisible—they're circular. The barrier isn't an expense that could be paid; it's a sequencing problem where the demonstration required to get funded is itself difficult to get funded. The cheapest questions to answer are often the ones that never get asked.

The tooling gap creates problems further down the study process too, particularly with recruitment. Most academic studies still enroll in person, which is slow, expensive in coordinator time, and produces a sample that's adequate rather than good. Travel is a measured cause of attrition: CISCRP survey data found that 44% of participants called traveling to a study clinic somewhat or very burdensome—up 15 points in two years—with 40% saying the same about visit length. And recruiting near campus means recruiting undergraduates and staff; Arnett found that as much as 80% of samples in APA-published studies were undergraduate psychology students. Mechanistic studies that never claimed to generalize are unaffected, but studies meant to say something about a broader population have that limit locked in at the design stage, before any statistical fix could apply later.

What This Decides

None of these constraints show up in the published record. What shows up is a protocol scoped down to what the tooling could support, a pilot that never ran because the pilot needed a pilot, a limitations paragraph about a college-age sample, and a dataset made shareable nine months after the last visit.

Decentralized infrastructure isn't right for every protocol. Studies that need supervised dosing, imaging, infusion, or clinical monitoring will stay site-based, and should. But the share of academic research that's site-based for logistical reasons rather than scientific ones is large—and the share paying to rebuild infrastructure that already exists elsewhere is larger. Both are decisions about tooling that end up being decisions about science.